Nicole Kruczek, RPh, MPBA

home / authors / nicole-kruczek-rph-mpba

Articles

Easy Reading: Direct and Indirect Remuneration Fees

Easy Reading: Direct and Indirect Remuneration Fees

Nicole Kruczek, RPh, MPBA
July 21st 2020

How a pharmacy performs with respect to specific measures can be associated with a DIR fee.

Read More

What is So ‘Special’ About Specialty Pharmacy?

What is So ‘Special’ About Specialty Pharmacy?

Nicole Kruczek, RPh, MPBA
July 1st 2020

The development and use of specialty pharmaceuticals have significantly affected global health care practices and costs.

Read More

Medication Adherence Programs: Strategies for Creating More Loyal Patients

Medication Adherence Programs: Strategies for Creating More Loyal Patients

Nicole Kruczek, RPh, MPBA;Ryan Stept, MSc
April 22nd 2020

Implementation of adherence programs can be effective in improving outcomes for patients and reduce costs both at the patient and systemic level.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD